Congratulations to LBCA Scientific Advisory Board member, Dr. Gary Ulaner on his election as President-Elect of the Society of Nuclear Medicine and Molecular Imaging, the world’s leading organization for nuclear medicine and molecular imaging professionals. The announcement was made during the Society’s 2026 Annual Meeting in Los Angeles earlier this month.
Dr. Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and a Professor at the University of Southern California. A nationally recognized leader in molecular imaging, he has played a key role in advancing imaging approaches that can improve the detection and management of invasive lobular carcinoma (ILC).
As a member of LBCA’s Scientific Advisory Board, Dr. Ulaner has been a strong advocate for lobular breast cancer research and helped establish a dedicated ILC imaging research grant partnership between SNMMI and LBCA. He also co-authored guidance on the appropriate use of FES-PET imaging, an emerging tool that may benefit some people diagnosed with ILC. We are proud to have Dr. Ulaner’s expertise and leadership helping to advance LBCA’s mission to increase awareness of invasive lobular carcinoma and the need for more research. Read more about Dr. Ulaner’s work for ILC here.
Dr. Megan Kruse Interviewed in JNCCN Peer Perspectives on Clinical Trial Updates in HR-Positive, HER2-Negative Breast Cancer
Dr. Kruse was recently interviewed by Drs. Jame Abraham for JNCCN Peer Perspectives in the Journal for National Comprehensive Cancer Network to discuss the findings from ongoing clinical trials with oral selective estrogen receptor degraders (SERDs) in combination with targeted inhibitors of CDK4/6, PI3K, mTOR, and AKT as well as the emerging role moving forward for these agents in the treatment of hormone receptor (HR)-positive, HER2-negative breast cancer.  Read the full interview to learn more here.